Skip to main content
Philogen logo

Philogen — Investor Relations & Filings

Ticker · PHIL ISIN · IT0005373789 LEI · 81560009EA1577917768 XMIL Manufacturing
Open in API
Filings indexed 375 across all filing types
Latest filing 2025-08-18 M&A Activity
Country IT Italy
Listing XMIL PHIL

About Philogen

https://www.philogen.com

Philogen is a clinical-stage biotechnology company focused on the discovery and development of novel biopharmaceutical products for the treatment of cancer and other serious conditions associated with angiogenesis. Founded in 1996, the company's core strategy is based on innovating targeted therapies, such as antibody-cytokine fusions, which are designed to selectively deliver therapeutic agents to the site of disease. This approach aims to increase efficacy while reducing toxicity. Philogen operates as an integrated company with capabilities in research, GMP manufacturing, and clinical development of its proprietary product pipeline.

Recent filings

Filing Released Lang Actions
Press Release Clearance e Closing OncoACP3 (Price Sensitive)
M&A Activity Classification · 100% confidence The document is a press release announcing the completion of an antitrust regulatory process (Hart-Scott-Rodino Act) and the subsequent effectiveness of a licensing agreement between Philochem AG (a subsidiary of Philogen) and RayzeBio (a subsidiary of Bristol-Myers Squibb). This is a corporate announcement regarding a strategic partnership and licensing deal, which falls under M&A/Strategic Transaction activity (TAR).
2025-08-18 Italian
2025 07 07 - CS settimanale acquisto azioni proprie
Transaction in Own Shares Classification · 100% confidence The document is titled 'AGGIORNAMENTO SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE' (Update on the Share Buyback Program) and details the number of own shares purchased during a specific period (June 30 to July 4, 2025). This directly corresponds to the definition of a company reporting transactions involving its own shares, which is classified as 'Transaction in Own Shares' (POS). The document provides detailed transaction logs and summary statistics, confirming it is the report itself, not just an announcement of a report (RPA/RNS).
2025-07-07 Italian
Allegato 3F
Director's Dealing Classification · 100% confidence The document is titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI" / "MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER'S SECURITIES". It details specific transactions (purchases 'A') involving the issuer's shares (PHILOGEN S.p.A.) by a third party (MEDIOBANCA-Banca di Credito Finanziario). This structure, focusing on insider or related-party transactions in the issuer's own stock, directly corresponds to the definition of Director's Dealing or insider transaction reporting, which is classified as 'DIRS' in the provided schema. The reference to transactions in own shares (POS) is usually for the issuer buying back shares, whereas this document details transactions by an external party concerning the issuer's stock.
2025-07-07 Italian
2025 06 30 - CS settimanale acquisto azioni proprie
Transaction in Own Shares Classification · 100% confidence The document is titled "AGGIORNAMENTO SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE" (Update on the Share Buyback Program) and details the number of shares purchased by Philogen S.p.A. between June 23 and June 27, 2025, including daily transaction logs. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The document is a formal announcement/report detailing these transactions, not just an announcement that a report is forthcoming (ruling 2 does not apply as this is the detailed report itself). Therefore, the appropriate code is POS.
2025-06-30 Italian
Philogen Provides Update on Marketing Authorization Application for Nidlegy™ in the European Union
Regulatory Filings Classification · 95% confidence The document is an announcement dated June 24, 2025, titled "Philogen Provides Update on Marketing Authorization Application for Nidlegy™ in the European Union." It explicitly states that the company has decided to "voluntarily withdraw the application for marketing authorization to the European Medicines Agency (EMA)" and plans to "resubmit an updated application." This is a specific corporate action update regarding regulatory submissions and clinical data status, not a full financial report (like 10-K or IR), an earnings release (ER), or a transcript (CT). Since it is a specific announcement about a regulatory/clinical development that doesn't fit the other specific categories (like M&A, Dividend, Director Dealing), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for significant, non-standard announcements, or potentially a Legal/Regulatory update (LTR). Given the context is a voluntary withdrawal of an MAA, which is a regulatory event, RNS is the most appropriate general classification for significant, non-financial regulatory news that isn't a lawsuit (LTR). The document length is substantial (nearly 6000 characters), so it is the report itself, not just an announcement of a report (RPA). I will classify it as RNS as it is a significant regulatory update that doesn't match the other specific codes.
2025-06-25 English
Press Release Licenza OncoACP3 (Price Sensitive)
Regulatory Filings Classification · 100% confidence The document is a press release dated June 10, 2025, announcing a major licensing agreement between Philochem AG (a subsidiary of Philogen S.p.A.) and RayzeBio (a Bristol-Myers Squibb company) concerning the drug candidate OncoACP3 for prostate cancer. The announcement details the financial terms, including an upfront payment, milestone payments up to $1.35 billion, and royalties. This type of announcement, detailing a significant corporate transaction involving licensing rights and substantial financial consideration, falls under the category of corporate financing or capital structure changes, as it directly impacts the company's future revenue streams and strategic direction. While it is a major corporate event, it is not a standard regulatory filing like a 10-K or an earnings release. It most closely aligns with 'Capital/Financing Update' (CAP) as it describes a major deal structure involving significant potential capital inflow and licensing rights transfer. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a management report (MDA) which usually accompanies periodic financial results.
2025-06-10 Italian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.